Immunoendocrine Abnormalities in Narcolepsy

Sleep Medicine Clinics

Volumn 2, Issue 2, 2007, Pages 293-302

  Pollmächer, Thomas ^a,b   Dalal, Mira A ^b   Schuld, Andreas ^a  

^a KLINIKUM INGOLSTADT   (Germany)

^b MAX PLANCK INSTITUTE OF PSYCHIATRY   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

GONADORELIN; GROWTH HORMONE; INTERLEUKIN 6; OREXIN; TUMOR NECROSIS FACTOR ALPHA;

AUTOIMMUNITY; DAYTIME SOMNOLENCE; DIABETES MELLITUS; ENDOCRINE DISEASE; ENERGY BALANCE; GENETIC PREDISPOSITION; GENETIC SUSCEPTIBILITY; GLUCOSE INTOLERANCE; GROWTH HORMONE RELEASE; HORMONAL REGULATION; HUMAN; IMMUNOPATHOLOGY; METABOLIC SYNDROME X; NARCOLEPSY; NEUROMODULATION; OBESITY; PATHOPHYSIOLOGY; PRIORITY JOURNAL; REM SLEEP; REVIEW; SLEEP WAKING CYCLE;

EID: 61449119034     PISSN: 1556407X     EISSN: 15564088     Source Type: Journal    
DOI: 10.1016/j.jsmc.2007.03.002     Document Type: Review

References (70)

1. Westphal C. Zwei Krankheitsfälle. Arch Psychiatr Nervenkr 7 (1877) 622-635 [German]
2. Gèlineau J. De la narcolepsie. Gazette des Hôpitaux 53 (1880) 635-637 [French]
3. American Sleep Disorders Association. The International Classification of Sleep Disorders revised. 1997.
4. Daniels L.E. Narcolepsy. Medicine 13 (1934) 1-122
5. Honda Y., Asaka A., Tanaka Y., et al. Discrimination of narcoleptic patients by using genetic markers and HLA. In: Chase M.H., Webb W.B., and Wilder-Jones R. (Eds). Sleep research (1983), UCLA Brain information Service, Brain Research Institute, Los Angeles (CA) 254-258
6. Honda Y. HLA in narcolepsy. In: Honda Y., and Juji T. (Eds). HLA in narcolepsy (1988), Springer-Verlag, Berlin 24-57
7. Mignot E. Genetic and familial aspects of narcolepsy. Neurology 50 2 Suppl 1 (1998) S16-S22
8. Pollmächer T., Schulz H., Geisler P., et al. DR-2-positive monozygotic twins discordant for narcolepsy. Sleep 13 (1990) 336-343
9. Dauvilliers Y., and Tafti M. Molecular genetics and treatment of narcolepsy. Ann Med 38 (2006) 252-262
10. Nishino S., Ripley B., Overeem S., et al. Hypocretin (orexin) deficiency in human narcolepsy. Lancet 355 9197 (2000) 39-40
11. Dalal M.A., Schuld A., Haack M., et al. Normal plasma levels of orexin a (hypocretin-1) in narcoleptic patients. Neurology 56 12 (2001) 1749-1751
12. Sakurai T. Orexins and orexin receptors: implication in feeding behavior. Regul Pept 85 1 (1999) 25-30
13. Peyron C., Faraco J., Rogers W., et al. A mutation in a case of early onset narcolepsy and a generalized absence of hypocretin peptides in human narcoleptic brains. Nat Med 6 9 (2000) 991-997
14. Lu J., Greco M.A., Shiromani P., et al. Effects of lesions of the ventrolateral preoptic nucleus on NREM and REM sleep. J Neurosci 20 (2000) 3830-3842
15. Kilduff T.S., and Peyron C. The hypocretin/orexin ligand-receptor system: implications for sleep and sleep disorders. Trends Neurosci 35 (2000) 359-365
16. Aldrich M.S. Diagnostic aspects of narcolepsy. Neurology 50 2 Suppl 1 (1998) S2-S7
17. Overeem S., Verschuuren J.J., Fronczek R., et al. Immunohistochemical screening for autoantibodies against lateral hypothalamic neurons in human narcolepsy. J Neuroimmunol 174 1-2 (2006) 187-191
18. *0602-positive narcoleptic subjects with cataplexy. Biol Psychiatry 58 (2005) 504-509
19. Tanaka S., Honda Y., Inoue Y., et al. Detection of autoantibodies against hypocretin, hcrtrl, and hcrtr2 in narcolepsy: anti-Hcrt system antibody in narcolepsy. Sleep 29 5 (2006) 633-638
20. Fredrikson S., Carlander B., Billiard M., et al. CSF immune variables in patients with narcolepsy. Acta Neurol Scand 81 (1990) 253-254
21. Schuld A, Uhr M, Pollmächer T. Oligoclonal bands and specific antibody indices in human narcolepsy. Somnologie/Somnology 2005;8:71-4.
22. Smith A.J.F., Jackson M.W., Neufing P., et al. A functional autoantibody in narcolepsy. Lancet 364 (2004) 2122-2124
23. Nishino S., Ripley B., Overeem S., et al. Low cerebrospinal fluid hypocretin (orexin) and altered energy homeostasis in human narcolepsy. Ann Neurol 50 (2001) 381-388
24. Overeem S., Dalmau J., Bataller L., et al. Hypocretin-1 CSF levels in anti-Ma2 associated encephalitis. Neurology 62 (2004) 138-140
25. Overreem S., Kok S.W., Lammers G.J., et al. Somatotropic axis in hypocretin-defient narcoleptic humans: altered circadian distribution of GH-secretory events. Am J Physiol Endocrinol Metab 284 (2003) E641-E647
26. Boehmer L.N., Wu M.F., John J., et al. Treatment with immunosuppressive and anti-inflammatory agents delays onset of canine genetic narcolepsy and reduces symptom severity. Exp Neurol 188 2 (2004) 292-299
27. Dauvilliers Y., Carlander B., Rivier F., et al. Successful management of cataplexy with intravenous immunoglobulins at narcolepsy onset. Ann Neurol 56 (2004) 905-908
28. Dauvilliers Y. Follow-up of four narcolepsy patients treated with intravenous immunoglobulins. Ann Neurol 60 (2006) 153
29. Hohjoh H., Nakayama T., Ohashi J., et al. Significant association of a single nucleotide polymorphism in the tumor necrosis factor-alpha (TNF-alpha) gene promoter with human narcolepsy. Tissue Antigens 54 2 (1999) 138-145
30. Wieczorek S., Gencik M., Rujescu D., et al. TNFA promoter polymorphisms and narcolepsy. Tissue Antigens 61 6 (2003) 437-442
31. Hohjoh H., Terada N., Kawashima M., et al. Significant association of the tumor necrosis factor receptor 2 (TNFR2) gene with human narcolepsy. Tissue Antigens 56 5 (2000) 446-448
32. Hinze-Selch D., Wetter T.C., Zhang Y., et al. In vivo and in vitro immune variables in patients with narcolepsy and HLA-DR2 matched controls. Neurology 50 4 (1998) 1149-1152
33. Okun M.K., Giese S., Lin L., et al. Exploring the cytokine and endocrine involvement in narcolepsy. Brain Behav Immun 18 (2004) 326-332
34. Vgontzas A.N., Bixler E.O., Lin H.M., et al. IL-6 and its circadian secretion in humans. Neuroimmunomodulation 12 (2005) 131-140
35. Himmerich H., Beitinger P.A., Fulda S., et al. Plasma levels of tumor-necrosis factor alpha and soluble tumor necrosis factor receptors in patients with narcolepsy. Arch Intern Med 166 (2006) 39-43
36. Date Y., Ueta Y., Yamashita H., et al. Orexins, orexigenic hypothalamic peptides, interact with autonomic, neuroendocrine and neuroregulatory systems. Proc Natl Acad Sci U S A 96 (1999) 748-753
37. Chen C.T., Dun S.L., Kwok E.H., et al. Orexin A-like immunoreactivity in the rat brain. Neurosci Lett 260 (1999) 161-164
38. Nambu T., Sakurai T., Mizukami K., et al. Distribution of orexin neurons in the adult rat brain. Brain Res 827 (1999) 243-260
39. Peyron C., Tighe D.K., Den Pol A.N., et al. Neurons containing hypocretin (orexin) project to multiple neuronal systems. J Neurosci 18 (1998) 9996-10015
40. Powley T.L., and Keesey R.E. Relationship of body weight to the lateral hypothalamic feeding syndrome. J Comp Physiol Psychol 70 (1970) 25-36
41. Bernadis L.L., and Bellinger L.L. The lateral hypothalamic area revisited: neuroanatomy, body weight regulation, neuroendocrinology and metabolism. Neurosci Biobehav Rev 17 (1993) 141-193
42. Hara J., Beuckmann C.T., Nambu T., et al. Genetic ablation of orexin neurons in mice results in narcolepsy, hypophagia and obesity. Neuron 30 (2001) 345-354
43. Schuld A., Hebebrand J., Geller F., et al. Increased body-mass index in patients with narcolepsy. Lancet 355 (2000) 1274-1275
44. Lammers G.J., Pijl H., Iestra J., et al. Spontaneous food choice in narcolepsy. Sleep 19 (1996) 75-76
45. Kok S.W., Meinders A.E., Overeem S., et al. Reduction of plasma leptin levels and loss of its circadian rhythmicity in hypocretin (orexin) deficient narcoleptic humans. J Clin Endocrinol Metab 87 (2002) 805-809
46. Schuld A., Blum W.F., Uhr M., et al. Reduced leptin levels in human narcolepsy. Neuroendocrinology 72 4 (2000) 195-198
47. Kok S.W., Roelfsema F., Overeem S., et al. Altered setting of the pituitary-thyroid ensemble in hypocretin-deficient narcoleptic men. Am J Physiol Endocrinol Metab 288 (2005) 892-899
48. Brunton P.J., and Russell J.A. Hypothalamic-pituitary-adrenal responses to centrally administered orexin-a are suppressed in pregnant rats. J Neuroendocrinol 15 (2003) 633-637
49. Van Cauter E., Plat L., and Copinschi G. Interrelations between sleep and the somatotropic axis. Sleep 21 (1998) 553-566
50. Fadel J., Bubser M., and Deutch A.J. Differential activation of orexin neurons by antipsychotic drugs associated with weight gain. J Neurosci 22 (2002) 6742-6746
51. Russell S.H., Kim S.M., Small C.J., et al. Central administration of orexin a suppresses basal and domperidone stimulated plasma prolactin. J Neuroendocrinol 12 (2000) 1213-1218
52. Lechan R.M., and Jackson I.M. Immunohistochemical localization of thyrotropin-releasing hormone in the rat hypothalamus and pituitary. Endocrinology 111 (1982) 55-65
53. Romijn J.A., Adriaanse R., Brabant G., et al. Pulsatile secretion of thyrotropin during fasting: a decrease of thyrotropin pulse amplitude. J Clin Endrocrinol Metab 70 (1990) 1631-1636
54. Blake N.G., Johnson M.R., Eckland D.J., et al. Effect of food deprivation and altered thyroid status on the hypothalamic-pituitary-thyroid axis in the rat. J Endocrinol 133 (1992) 183-188
55. Cai X.J., Widdowson P.S., Harrold J., et al. Hypothalamic orexin expression: modulation by blood glucose and feeding. Diabetes 48 (1999) 2132-2137
56. Blum W.F. Leptin-the voice of the adipose tissue. Horm Res 48 Suppl 4 (1997) 2-8
57. Schwartz M.W., Woods S.C., Porte D., et al. Central nervous system control of food intake. Nature 404 6778 (2000) 661-671
58. Yamamoto Y., Ueta Y., Date Y., et al. Down regulation of the prepro-orexin gene expression in genetically obese mice. Brain Res Mol Brain Res 65 1 (1999) 14-22
59. Arnulf I., Lin L., Zhang J., et al. CSF versus serum leptin in narcolepsy: is there an effect of hypocretin deficiency?. Sleep 29 8 (2006) 1017-1024
60. Roberts H.J. The syndrome of narcolepsy and diabetogenic hyperinsulinism in the American negro: its relationship to the pathogenesis of diabetes mellitus, obesity, dysrhythmias, and accelerated cardiovascular disease. J Natl Med Assoc 56 (1964) 18-42
61. Honda Y., Doi Y., Ninomiya R., et al. Increased frequency of non-insulin-dependent diabetes mellitus among narcoleptic patients. Sleep 9 (1986) 254-259
62. Siegel J.M. Narcolepsy: a key role for hypocretins (orexins). Cell 98 4 (1999) 409-412
63. Dahmen N., Bierbrauer J., and Kasten M. Increased prevalence of obesity in narcoleptic patients and relatives. Eur Arch Psychiatry Clin Neurosci 251 2 (2001) 85-89
64. Bell J.I. Diet histories in narcolepsy. In: Guilleminault C., Dement W.C., and Passouant P. (Eds). Narcolepsy-proceedings of the first international symposium on narcolepsy 1975 (1976), SP Books Division of Spectrum Publications, New York 221-227
65. Boudoulas H., Schmidt H.S., Clark R.W., et al. Anthropometric characteristics, cardiac abnormalities and adrenergic activity in patients with primary disorders of sleep. J Med 14 (1983) 223-238
66. Kotagal S., Hartse K.M., and Walsh J.K. Characteristics of narcolepsy in preteenaged children. Paediatrics 85 (1990) 205-209
67. Dahl R.E., Holttum J., and Trubnick L. A clinical picture of child and adolescent narcolepsy. J Am Acad Child Adolesc Psychiatry 33 (1994) 834-841
68. Schuld A., Beitinger P., Hebebrand J., et al. Increased Body Mass Index (BMI) in male narcoleptic patients, but not in HLA-DR2-positive healthy male volunteers. Sleep Med 3 (2002) 335-339
69. Kok S.W., Overeem S., Visscher T.L., et al. Hypocretin deficiency in narcoleptic humans is associated with abdominal obesity. Obes Res 11 (2003) 1147-1154
70. Doelle G.C. The clinical picture of metabolic syndrome. An update on this complex of conditions and risk factors. Postgrad Med 116 (2004) 30-32 35-8